Buy & Sell Direxion Daily TSLA Bull 2X Shares (TSLL) – Direxion Daily TSLA Bull 2X Shares Price Today
Aura AI Summary
Key Stats
- -Market Cap
- Leveraged / InverseSector
- -31.35%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 51% Buy | 49% SellTrading Activity
- 8 daysTypical Hold Time
Over the past 52 weeks, Direxion Daily TSLA Bull 2X Shares has traded between a low of $9.98 and a high of $23.03, highlighting its annual price range. Over the past three months, Direxion Daily TSLA Bull 2X Shares has recorded a drawdown of -31.35%, reflecting recent price volatility. On average, investors hold Direxion Daily TSLA Bull 2X Shares for approximately 8 days, indicating typical investor behavior on the platform.
About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Most Recent News
Investigation into Wealthfront's securities fraud continues amid sharp stock drops and deposit declines.
Glancy Prongay & Murray LLP is investigating Wealthfront Corporation for potential securities law violations after the company reported significant financial setbacks. Wealthfront's stock fell sharply following disclosures of large net deposit outflo...

ControlUp named Leader for third year in Gartner's 2026 Digital Employee Experience Magic Quadrant.
ControlUp has been recognized as a Leader for the third consecutive year in Gartner's 2026 Magic Quadrant for Digital Employee Experience (DEX) Management Tools. This highlights ControlUp's innovation in Autonomous Endpoint Management using agentic A...

Gilead and Merck halt lung cancer trial but report positive HIV drug Phase 3 results.
Gilead Sciences and Merck have stopped their Phase 3 trial combining Trodelvy and Keytruda for metastatic non-small cell lung cancer after it failed to show statistically significant benefits. However, they announced positive Phase 3 results for a ne...
